USPTO serial 77237564
PHARMAFILM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- DAWE III, WILLIAM H
- Law office
- TMEG LAW OFFICE 108 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with PHARMAFILM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Saint-Laurent, Quebec, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
ERIC B MEYERTONS
ERIC B MEYERTONS MEYERTONS HOOD KIVLIN KOWERT & GOETZEL PPO BOX 398AUSTIN, TX 78767-0398UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for the prevention and treatment of diseases and disorders of the respiratory system, central nervous system, peripheral nervous system, cardiovascular system, gastro-intestinal system; Pharmaceutical preparations and substances for use in pain control and pain management, arthritis, anesthesia, asthma, oncology, urology, gynecology; Pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; Pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases and arthritis; Pharmaceutical preparations and substances for the treatment and prevention of diabetes; Chemicals relating to drug performance and/or drug delivery performance for research use and manufacturing in the biotechnical, biomedical and pharmaceutical industries; Inhalers and applicators for the prevention and treatment of diseases and disorders of the respiratory system, central nervous system, peripheral nervous system, cardiovascular system, gastro-intestinal system; Inhalers and applicators for use in pain control, asthma treatment, arthritis, anesthesia, oncology, infection, inflammation, urology, gynecology, dental care, surgery and radiology; Inhalers and applicators for the treatment and prevention of diabetes; Apparatus and instruments for use in pain control and pain management, arthritis, asthma, anesthesia, oncology, infection, inflammation, urology, gynecology, dental care, surgery respiratory system, central nervous system, peripheral nervous system, cardiovascular system, gastro-intestinal system and radiology; apparatus and instruments for the treatment and prevention of diabetes; prepared and processed proteins and myco-proteins for human consumption; Medical devices, namely, medical apparatus, namely, a unit for aerosol drug delivery to the deep lung of drugs as fine, dry particles; Chemicals for use in the manufacture of pharmaceuticals, namely, peptides, polypeptides, molecules, enzymes substrates, natural extracts, active principles, reactives, solvents, metals, metalloids; chemicals for use in the manufacture of cosmetics; Pharmaceutical, veterinary and sanitary preparations and dietetic substances adapted for medical use, namely, psychotropic, cardiovascular agents, vasotherapeutics in the form of ampoule, tablets or liquid, anti-infective, antibiotics, chemotherapeutics, antiviral agents, hormones, metabolic agents in the form of caplets or liquid or particulate inhaleable formulation, namely, peptides, polypeptides, opiods, opiod derivatives, pain agents, amino acids, peptides, creatine, dextrose, vitamin C, antidiabetic drugs, agents for digestive disorders, namely, antiacids, anti-diarrhea and antiemetics in the form of liquid or caplets, antiallergic drugs, analgesics, spasmolytic drugs, narcotics, anesthetics, antiphlogistic, antirheumatic and anti asthmatic agents; Dermatological preparations, namely, creams for the treatment of pain, acne, eczema, dry skin, psoriasis and other immune system controlling agents, namely, vaccines, drugs to treat osteoporosis, tumor therapeutics; Biological products, namely, for pharmaceutical, clinical or medical laboratory use, namely, biological reagents for diagnostic and scientific purposes, antiemetics, pain treatment drugs, vaccines, infusions of said drugs; Plasters, namely, material plasters, adhesive plasters, mucosa plasters, drug bearing plasters and films, materials for dressings; material for stopping teeth: Surgical, medical, dental and veterinary apparatus and instruments, namely, aerosol dispensers for medical purposes, injectors for medical purposes, pumps for medical purposes; tissues and materials impregnated with pharmaceutical substances, namely, opiod bearing films; Pharmaceutical and veterinary products in the form of caplets, liquid to be administrated by injection, liquid to be orally administrated for the prevention and treatment of obesity, smoking cessation, nephropathy, pulmonary embolism, atherothrombosis, asthma, hypertension, thrombosis, arrhythmia, angina, hypertension, heart failure, insomnia, epilepsy, schizophrenia, fever and pain; Pharmaceutical preparations for the treatment of the central nervous system, namely, neurotic and psychosomatic disorder, namely, anxiety, depression, hysteria, stress, fears; prostatic hyperplasia, granuloma inguinale, bilharziasis, and other protozoal infections, namely, babesios, coccidiosis, cryptosporidiosis, malaria, toxoplasmosis, trichomoniasis, trypanosomiasis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 7, 2008 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 6, 2008 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 18, 2007 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 18, 2007 | ALIE | ASSIGNED TO LIE | — |
| Nov 6, 2007 | PAPER RECEIVED | — | |
| Oct 9, 2007 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 9, 2007 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 2, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 27, 2007 | NWAP | NEW APPLICATION ENTERED | — |